Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bodewell Products for Atopic Dermatitis
NCT05566262Phase 4Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Bodewell Calming Cream in atopic dermatitis (AD), sponsored by University of Alabama at Birmingham. Primary endpoint: Patient Global Assessment at 12 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
Bodewell Calming Cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05566262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566262.